Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole Repurposing in High-risk Barrett's Esophagus
NCT05609253Phase 1Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Sep 2022
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of itraconazole in Barrett's esophagus (2 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Itraconazole drug and blood levels. Started Sep 2022; status: active, not recruiting.
02
Drugs
itraconazole
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT05609253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609253.